| | ./ | | | | | | | | |
|----------------------|-----------|---------------------|------------------|---------------------------------------|-------------------------------|------|------------------------|----------------------|-------|
| TORTO | <u>/</u> | | | | | | | IEET_ | 1_0 |
| <u>торгон</u> 449 (М | Aodified) | | U.S. D | Department of Commerce | Atty. Docket No. 28967/348 | 91A | Serial No. 09/765,5 | 534 | |
| | | | | nt and Trademark Office | | | | | |
| INFOR | MAT | ION DISCLO | OSURE STAT | TEMENT | | | | | |
| | | (Use several sheets | s if necessary) | | | | | | |
| | | | | · · · · · · · · · · · · · · · · · · · | Applicant Alitalo et a | al. | | | |
| | | | | | Filing Date 1-19-01 | | Group 1644 | | |
| Initials | | Document Number | Issue Date | Name | | lass | Subclass | Filing If Appr | |
| Initials | | | | | | | | If | |
| y | A30 | 6,451,764 | 09/17/02 | Lee, et al. | 3 | 14 | 12 | | |
| | í | | 1 | TENT DOCU | MENTS | | | <u> </u> | |
| | l | | FOREIGN PAT | IBNI DOCO | | | | | |
| | | Document Number | Publication Date | Country | Class | Subo | lass | · Transla | ation |
| | | Document | Publication | | · , | | | Yes | N |
| Examiner Initials | | Document | Publication | | · , | | | Yes | N |
| Examiner Initials | | Document | Publication | | · , | | | Yes | N |

| OTHER DOC | UMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|--|
| | |
| EXAMINER | DATE CONSIDERED 6-3-07 |
| *EXAMINER: Initial if reference considered, w citation if not in conformance and not considere | whether or not citation is in conformance with MPEP 609; Draw line through ed. Include copy of this form with next communication to applicant. |

| OIPE | | SHEET 1 of 27 |
|--|----------------------------------|---------------------------|
| Form PTO-1449 (Modified) APR 2 6 2002 U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 |
| INFORMATION DESCRIPTION OF THE STATEMENT | Applicant Alitalo, K. et al. | (ED) |
| OIPE Wase several sheets if necessary) | Filing Date January 19, 2001 | Group ≥ 2, 6, 1644 Ш ≈ 11 |

APR 2 6 2002 **U.S. PATENT DOCUMENTS** Filing Date *Examiner Document Name Subclass Ιf Issue Class Initial Number Appropriate Date **A1** 4,543,439 09/24/85 Fracketton, Jr. et al. 435 70.21 A2 4,652,639 03/24/87 Stabinsky 536 27 A3 4,933,294 06/12/90 Waterfield et al. 436 501 A4 02/02/93 Kraus et al. 536 23.5 5,183,884 **A5** 5,185,438 02/09/93 Lemischka 536 23.2 **A6** 03/30/93 Taniguchi et al. 435 252.3 5,198,359 **A7** 07/27/93 Kaplan et al. 435 5,231,001 7.21 **A8** 5,256,766 10/26/93 Coughlin 530 327 **A9** 5,270,458 12/14/93 Lemischka 536 23.5 A10 5,283,354 02/01/94 Lemişchka 536 23.5 A11 11/22/94 5,367,057 Lemischka 530 350 A12 5,635,177 06/03/97 Bennett et al. 424 143.1 A13 5,643,759 07/01/97 435 70.21 Pfreundschuh, M. A14 5,693,762 12/02/97 Queen, C.L. et al. 530 387.3 A15 5,700,822 12/23/97 514 380 Hirth, K.P. et al. App, H. et al. A 16 5,712,395 01/27/98 544 344 A17 5,747,651 05/05/98 530 -Lemischka, I.R. 387.9 A18 5,750,078 05/12/98 Shitara. K. et al. 424 133.1

| FYAN | MINER | |
|------|----------|--|
| CAA | MILLIAEK | |

A19

5,763,441

DATE CONSIDERED

App, H. et al.

6-3-04

514

249

*EXAMINER:/Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/09/98

| | OIPE | | | SHEET 2 of 2 |
|--------------------------|---------------------------|--|----------------------------------|-----------------------|
| Form PTO-1449 (Modified) | APR 2 6 2002 | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 |
| INFORMATION | E / | TATEMENT | Applicant Alitalo, K. et al. | ÉD 002 |
| | several sheets if necessa | | Filing Date January 19, 2001 | Group ≥ 6 6 1644 Ш ≈ |
| | | | | O & |

| | U.S. PATENT DOCUMENTS | | | | | | r E |
|-----------------------|-----------------------|--------------------|---------------|-------------------------|-------|----------|----------------------------|
| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
| | A20 | 5,763,733 | 06/09/98 | Whitlow, M. et al. | 530 | 387.3 | |
| | A21 | 5,776,427 | 07/07/98 | Thorpe, P.E. et al. | 424 | 1.49 | |
| | A22 | 5,776,755 | 07/07/98 | Alitalo, K. et al. | 435 | 194 | |
| | A23 | 5,798,097 | 08/25/98 | McKenzie, I.F.C. et al. | 424 | 181.1 | |
| | A24 | 5,807,548 | 09/15/98 | Shitara, K. et al. | 424 | 133.1 | |
| | A25 | 5,952,199 | 09/14/99 | Davis-Smyth et al. | 435 | 69.7 | |
| | A26 | 6,011,003 | 01/04/00 | Charnock-Jones et al. | 514 | 2 | |
| · | A27 | 6,107,046 | 08/22/00 | Alitalo, K. et al. | 435 | 7.1 | |
| | A28 | 6,130,071 | 10/10/00 | Alitalo, K. et al. | 435 | 69.4 | |
| | A29 | 6,331,302 | 12/18/01 | Bennett, et al. | 424 | 146.1 | · |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|------------|--------------------|---------------------|---------|-------|----------|------|---------|
| | , | | | | | | Trar | slation |
| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Yes | No |
| V | B1 | EP 0 325 224 A2 | 07/26/89 | EPO | - | | | |
| 19 | B2 | WO 90/14425 | 11/29/90 | WIPO | - | | | |
| | B 3 | WO 92/13867 | 08/20/92 | WIPO | i . | | | |
| | B4 | WO 92/14748 | 03/09/92 | WIPO | . \ | | | |

| | 4 | | | |
|----------|---|-----------------|-------|---|
| EXAMINER | / | DATE CONSIDERED | 6-1-0 | 7 |
| | | | | |

| | | SHEET 3 01 27 |
|---|----------------------------------|--------------------------|
| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 |
| APR 2 6 2002 L | Applicant Alitalo, K. et al. | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Filing Date January 19, 2001 | Group 1644 |

| | | FC | OREIGN PATE | ENT DOCU | JMENTS | | | |
|-----------------------|-----|--------------------|---------------------|----------|--------|----------|--------|---------------------------------------|
| | | | | | | | Тта | nslation |
| *Examiner Initia/s | | Document Number | Publication Date | Country | Class | Subclass | Yes | No |
| | B5 | WO 93/14124 | 07/22/93 | WIPO | | | | |
| /` | В6 | WO 93/15201 | 08/05/93 | WIPO . | | | | . S |
| | B7 | WO 94/10202 | 05/11/94 | WIPO | | | Ш | 2002 1600/2 |
| | B8 | WO 95/24473 | 09/14/95 | WIPO | | | _ ≥ | 9 2 R 16 |
| | В9 | WO 95/33772 | 12/14/95 | WIPO | _ | | Height | PR 2 ENTE |
| | B10 | WO 96/39515 | 12/12/96 | WIPO | | | RE | APR 2 9 2002 TECH CENTER 1600/2900 |
| | B11 | WO 97/05250 | 02/13/97 | WIPO | | | | 出 |
| | B12 | WO 97/09427 | 03/13/97 | WIPO | | | | |
| | B13 | WO 98/33917 | 08/06/98 | WIPO | | | | |
| | B14 | 98/07832 | 26/02/98 | wo | 6 | 4 | | |
| V | B15 | 99/33485 | 08/07/99 | wo | 6 | | | |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|----|--|
| P | C1 | Achen, M. G., et al., "Localization of Vascular Endothelial Growth Factor-D in Malignant Melanoma Suggests a Role in Tumour Angiogenesis," J. Pathol. 193(2): 147-54 (2001). |
| 1 | C2 | Achen, M.G. et al., "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," Eur. J. Biochem, 267(9):2505-15 (May, 2000). |

| EXAMINER | M | DATE CONSIDERED 6 3-07 |
|-------------------|--------------------------|--|
| *EVAMINED. Initio | Lif reference considered | hother are not sitution is in conformance with MDED 600. Draw line through |

| OIPE | | | SHEET 4 of 27 |
|--|--|----------------------------------|--------------------------|
| Form PTO-1449 (Modified) APR 2 6 2002 | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,584 |
| INFORMATION BISCOP SURI | C CTATEMENT | Applicant Alitalo, K. et al. | VE |
| (Use several sheets if necessor | | Filing Date January 19, 2001 | Group Ш ∾ 1644 () ∝ |
| | | | III 4 C |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|-----|--|
| | C3 | Achen, M.G. et al., "Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci., USA, 95(2):548-553 (January, 1998). |
| | | Akagi, K., et al., "Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues," Br. J. Cancer, 83(7):887-91 (October, 2000). |
| | C5 | Andre, T., et al., "Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa," Int. J. Cancer, 86(2):174-81 (April 15, 2000). |
| | C6 | Andersson et al., "Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines," In R. F. Revoltella (ed.), Expression of Differentiated Functions in Cancer Cells. 239-245, Raven Press, New York (1982). |
| C7 "Angiogenesis Inhibitors in Cancer Research," Cancer Trials, at cancertrials.nci.nih.gov/news/angio/fsangio/fsangio.html (visited Jan. 2 | | |
| | | "Angiogenesis Inhibitors in Clinical Trials," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Jan. 24, 2001). |
| C9 "Angiogenesis Inhibitors in Clinical Trials," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Sep. 25, 2001). | | |
| | C10 | "Angiogenesis Inhibitors in Clinical Trials: Expanded Trial Information," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Sep. 25, 2001). |
| | | Aprelikova et al., "FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," Cancer Research, 52(3):746-748 (February 1, 1992). |
| | C12 | Aujame, L. et al., "High affinity human antibodies by phage display," Human Antibodies, 8(4):155-168 (1997). |
| L | C13 | Banerji, S. et al., "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan," <i>J Cell Biol.</i> 144(4):789-801 (1999). |
| | | |

| | Λ | |
|----------|---|--|
| EXAMINER | | DATE CONSIDERED 6-3-07 |
| | | tion is in conformance with MPEP 609; Draw line through of this form with next communication to applicant. |

| OIPE | | | SHEET | 5 of 27 |
|---------------------------------------|--|----------------------------------|--------------------------|----------------|
| Form PTO-1449 (Modified) APR 2 6 2002 | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 | |
| INFORMATION DISCHOSURI | C CT A TENDENT | Applicant Alitalo, K. et al. | | 2800 |
| (Use several sheets if necessor | • | Filing Date January 19, 2001 | Group 1644 | 2002 200/29 |
| | <u>", </u> | | | |

| <u> </u> | | Se several sheets it necessary |
|----------|-----|---|
| | | TER 2 9 |
| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, et) |
| f- | C14 | Beckstead, J.H. et al., "Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium," Am. J. Pathol., 119(2):294-300 (May, 1985). |
| | C15 | Benz, C. C. et al., "Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu," Breast Cancer Res Treat. 24(2):85-95 (1993). |
| | C16 | Berridge et al., "Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIIa Glycoprotein Complex," Blood, 66(1):76-85 (July, 1985). |
| | C17 | Bolen, J.B., "Nonreceptor Tyrosine Protein Kinases," <i>Oncogene</i> , 8:2025-2031 (1993). |
| | C18 | Bolhuis, R.L. et al., "T cell targeting in cancer therapy," Cancer Immunology Immunotherapy, 34(1):1-8 (1991). |
| | C19 | Borg et al., "Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase," Oncogene, 10:973-984 (1995). |
| | C20 | Brown, L.F. et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer," Human Pathology, 26(1):86-91 (January, 1995). |
| | C21 | Brüggemann, M. et al., "Production of human antibody repertoires in transgenic mice," Curr. Opin. Biotechnol., 8:455-458 (1997). |
| | C22 | Brüggemann, M. et al., "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunol. Today, 17(8)</i> :391-397 (August, 1996). |
| | C23 | Bunone, G., et al., "Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features," Am. J. Pathol, 155(6):1967-76 (December 1999). |
| | C24 | Byrne, C. et al., "Programming Gene Expression in Developing Epidermis," Development, 120(9):2369-83 (1994). |

| EXAMINER | | DATE CONSIDERED 6-1-07 | | |
|---|--|------------------------|--|--|
| *EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

Serial No. Atty. Docket No. Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office 28967/34891A 09/765,534 APR 2 6 2002 INFORMATION DISCLOSURE STATEMENT Applicant Alitalo, K. et al. Filing Date Group January 19, 2001 1644 (Use several sheets if necessary)

| 4 | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, et 2 | |
|---|--|--|--|
| | C25 | Cantley et al., "Oncogenes and Signal Transduction," Cell, 64:281-302 (January 25, 1991). | |
| | C26 Cao, Y., et al., "Vascular Endothelial Growth Factor C Induces Angiogenesis in Vivo," Proc. Natl. Acad. Sci. USA, 95:14389-94 (November 1998). | | |
| | C27 | Carter, P. et al., "Toward the Production of Bispecific Antibody Fragments for Clinical Applications," <i>Journal of Hematotherapy</i> , 4:463-470 (1995). | |
| | C28 | Catoretti et al., "Monoclonal Antibodies Against Recombinant Parts of the Ki-67 Antigen (MIB 1 and MIB 3) Detect Proliferating Cells in Microwave-Processed Formalin-Fixed Paraffin Section," J. of Pathol., 168:357-363 (1992). | |
| | C29 | Cheng & Flanagan, "Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases," <i>Cell</i> , 79:157-168 (October 7, 1994). | |
| | C30 Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lun, Cancer," Monoclonal Antibodies and Cancer Therapy, Alan R Liss, Inc., pp. 77 (1985). | | |
| | C31 | Collins et al., "Continuous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture," Nature, 270:347-349 (1977). | |
| | C32 | De Gast, G.C. et al., "Clinical perspectives of bispecific antibodies in cancer," Cancer Immunol Immunother, 45:121-123 (1997). | |
| | C33 | De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science, 255:989-991 (February 21, 1992). | |
| F | C34 | De Waal, R. et al., "Technical Advance: Lack of Lymphangiogenesis in Human Primary Cutaneous Melanoma," American Journal of Pathology, 150(6):1951-1957 (June, 1997). | |
| L | C35 | Devereux et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," Nucleic Acids Res., 12(1):387-395 (1984). | |

| | / | |
|----------|---|------------------------|
| EXAMINER | | DATE CONSIDERED 6-3-07 |
| | · | |

Form PTO-1449 (Modified)

APR 2 6 2002

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant

Alitalo, K. et al.

VEC 2002

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

Filing Date

January 19, 2001

Group ≤ 55 1644 Ш ≈

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Dictor, M. et al., "Lymphaticovenous Differentiation in Kaposi's Sarcoma: Cellular C36 Phenotypes by Stage," American Journal of Pathology, 130(2):411-417 (February, 1988). C37 Dignam et al., "Balbiani Ring 3 in Chironomus Tentans Encodes a 185-kDa Secretory Protein Which Is Synthesized Throughout the Fourth Larval Instar," Gene, 88:133-40 (1990). C38 Dumont, D. J. et al., "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," Science, 282(5390):946-49 (1998). C39 Edgell et al., "Permanent Cell Line Expressing Human Factor VIII-Related Antigen Established by Hybridization," Proc. Nat'l. Acad. Sci. USA, 50:3734-3737 (June, 1983). Egeblad, M. and Jaattela, M. "Cell death induced by TNF or serum starvation is C40 independent of ErbB receptor signaling in MCF-7 breast carcinoma cells," Int J Cancer, 86(5):617-25 (2000). C41 Eggert, A., et al., "High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas," Clin. Cancer Res., 6(5):1900-8 (May 2000). C42 Eichmann et al., "Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules," Gene, 174(1):3-8 (1996). C43 Enholm, B. et al., "Vascular Endothelial Growth Factor-C, a Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," TCM, 8(7):292-297 (1998). C44 Fanger, M.W. et al., "Bispecific Antibodies," Critical Reviews in Immunology, 12(3,4):101-124 (1992). C45 Fellmer, P.T., et al., "Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas," Surgery, 126(6):1056-61 (December 1999).

| | ∠ | | |
|-------------|---|-----------------|--------|
| EXAMINER | | DATE CONSIDERED | 6-3-04 |

| OIPE | | | SHEET 8 c | of 27 |
|--|--|----------------------------------|--------------------------|-------|
| Form PTO-1449 (Modified) APR 2 5 2002 | U.S. Department of Commerce Patent and Trademark Office | Aity. Docket No. 28967/34891A | Serial No. 09/765,534 | |
| INFORMATION DESCRIPTION OF THE PROPERTY OF THE | STATEMENT | Applicant Alitalo, K. et al. | 0 | OOO |
| (Use several sheets if necessary | , | Filing Date January 19, 2001 | Group | רטטלא |
| | | | U: | 2 |

| | | O & |
|----------|-----|--|
| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
| | C46 | Ferrara, N. et al., "The Biology of Vascular Endothelial Growth Factor," Endocrine Reviews, 18(1):4-25 (1997). |
| | C47 | Ferrara, N. et al., "Molecular and Biological Properties of Vascular Endothelial Growth Factor," J Mol Med., 77(7):527-43. (1999). |
| | C48 | Fielder W., et al., "Expression of FLT4 and its ligand VEGF-C in Acute Myeloid Leukemia," Leukemia, 8:1234-7 (August 1997) (Abstract). |
| | C49 | Finnerty et al., "Molecular Cloning g of Murine FLT and FLT4," Oncogene, 8(11):2293-2298 (1993). |
| , | C50 | Flanagan & Leder, "The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," Cell, 63:185-194 (October 5, 1990). |
| | C51 | Folkman et al., "Long-term culture of capillary endothelial cells," Proc. Nat'l Acad. Sci., USA, 76(10):5217-5221 (October, 1979). |
| | C52 | Folpe, A.L., et al., "Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas," Mod. Pathol, 13(2):180-185 (2000). |
| | C53 | Foote, J. et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," J. Mol. Biol., 224:487-499 (1992). |
| | C54 | Fortkamp et al., "Cloning and Expression in Escherichia coli of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor in the Leech," DNA, 5(6):511-517 (1986). |
| | C55 | Fournier et al., "Mutation at Tyrosine Residue 1337 Abrogates Ligand-Dependent Transforming Capacity of the FLT4 Receptor," Oncogene, 11:921-931 (1995). |
| X | C56 | Fournier et al., "Interaction with the Phosphotyrosine Binding Domain/Phosphotyrosine Interacting Domain of SHC Is Required for the Transforming Activity of the FLT4/VEGFR3 Receptor Tyrosine Kinase," J. Biological Chemistry, 271 (22):12956-12963 (1996). |

| EXAMINER (| | DATE CONSIDERED | 6 3-04 |
|-------------------|----------|-----------------|--------|
| *EVANDED 1 11 115 | <i>.</i> | | |

| | | | · · · · · |
|---|----------------------------------|--------------------------|-----------|
| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 | |
| INFORMATION PISCLOSTRE STATEMENT | Applicant Alitalo, K. et al. | | |
| INFORMATION DISCLOSTRE STATEMENT (Use several sheets if necessary) | Filing Date January 19, 2001 | Group 1644 | 9 2002 |
| | | Ш Ш | PR 2 |
| OTHER DOCUMENTS (Including A | uthor, Title, Date, Pertinen | t Pages, etc.) | A |
| C57 Gahmherg at al. "Membrane Glycolysat | ion During Cell Differ | rentiation " In 1 | |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---------------|------------|---|
| y | C57 | Gahmberg et al., "Membrane Glycolysation During Cell Differentiation," In L. C. Andersson, et al. (ed.), Gene Expression During Normal and Malignant Differentiation, 107-123, Academic Press, London (1985). |
| \mathcal{J} | C58 | Galland et al., "Chromosomal Localization of FLT4, a Novel Receptor-Type Tyrosine Kinase Gene," Genomics, 13:475-478 (1992). |
| | C59 | Galland et al., "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," Oncogene, 8(11):1233-1240 (1993). |
| 7 | C60 | Gasparini, G. et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, 13(3):765-782 (March, 1995). |
| | C61 | Genbank Accession X51602 Human flt mRNA for receptor-related tyrosine kinase, deposited by Shibuya, M. |
| | C62 | Genbank Accession X60280 plasmid pLTRpoly, deposited by Mackelae et al. |
| | C63 | Genbank Accession X68203 H. sapiens mRNA for FLT4, Class III receptor tyrosine kinase, deposited by Aprelikova, O. |
| | C64 | Genbank Accession X83287 C. coturnix Quek2 mRNA for vascular endothelial growth factor receptor, deposited by Eichmann, et al. |
| | C64 | GenBank Accession No. AF014827, Rattus norvegicus vaseular endothelial growth factor D (VEGF-D) mRNA, deposited by Yamada, Y. |
| | <u>C65</u> | GenBank Accession No. A1000185, Home Sapiens mRNA for vascular endothelial growth factor-D, deposited by Achen, M.G. |
| | C66 | GenBank Accession No. CCY15837, Coturnix coturnix mRNA for vascular endothelial growth factor C, deposited by Eichmann, A. |
| | C67 | GenBank Accession No. D89628, Mus musculus mRNA for vascular endothelial growth factor D, deposited by Yamada, Y. |

| EXAMINER | DATE CONSIDERED 6-1-47 | | | |
|---|------------------------|--|--|--|
| *EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

Form PTO-1449 (Modified) **URE STATEMENT INFORMATION**

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

(Use several sheets if necessary)

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|-----|--|
| • | C68 | GenBank Accession No. MMU73620, Mus musculus VEGF-C mRNA, complete cds., deposited by Kukke, E. |
| 1 | C69 | Greenberg et al., "Characterization of a New Megakaryocyte Cell Line: The Dami Cell," Blood, 72(6):1968-1977 (December, 1988). |
| | C70 | Gunningham, S.P., et al., "The Short Form of the Alternatively Spliced flt-4 but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers," Clin. Cancer Res., 6(11):4278-86 (November 2000). |
| | C71 | Harlow et al., Antibodies: A Laboratory Manual, pp.7-25, 72-137, 141-157, 287 & 321-358 (1988). |
| | C72 | Hatva et al., "Expression of Endothelial Cell-Specific Receptor Tyrosine Kinases and Growth Factors in Human Brain Tumors," Am. J. Pathol., 146:368-378 (1995). |
| | C73 | Hatva, E., et al., "Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas," Am. J. Pathol, 148(3):763-75 (March 1996). |
| | C74 | Heldin et al., "Platelet-Derived Growth Factor: Mechanism of Action and Possible in Vivo Function," Cell Regulation, 1:555-566 (July, 1990). |
| | C75 | Hemmila et al., "Europium as a Label in Time-Resolved Immunofluorometric Assays," Annal. Biochem, 137:335-343 (1984). |
| · | C76 | Hewett, P.W. et al., "Coexpression of flt-1, flt-4 and KDR in Freshly Isolated and Cultured Human Endothelial Cells," Biochemical and Biophysical Research Communications, 221:697-702 (1996). |
| | C77 | Hirai et al., "A Novel Putative Tyrosine Kinase Receptor Encoded by the eph Gene," Science, 238:1717-1720 (1987). |
| | C78 | Hirai, M. et al., "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endomatrial Carcinoma," Gynecol. Oncol. 80(2):181-8 (February, 2001). |

| EXAMINER | DATE CONSIDERED 6 3-47 |
|----------|------------------------|
| | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | OIPE | |
|--------------------------|--------------|--|
| Form PTO-1449 (Modified) | APR 2 6 2002 | U.S. Department of Commerce Patent and Trademark Office |
| INFORMATIO | N DISCEPTSUR | E STATEMENT |

(Use several sheets if necessary)

Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C79 Hoogenboom, H.R., "Designing and optimizing library selection strategies for generating high-affinity antibodies," TIBTECH, 15:62-70 (1997). C80 Hu; Jing-Shan, et al., "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells," The FASEB Journal, 11:498-504 (May 1997). C81 Huang et al., "The Hematopoietic Growth Factor KL is Encoded by the SI Locus and is the Ligand of the c-kit Receptor, the Gene Product of the W Locus," Cell, 63:225-33 (October 5, 1990). C82 Hunter & Greenwood, "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," Nature, 194(4827):495-496 (May 5, 1962). C83 IMC-1C11, ImClone Systems Incorporated, at www.imclone.com/imc1c11.html (visited Sep. 25, 2001). C84 Irrthum, A. et al., "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.," Am J Hum Genet. 67(2):295-301 (2000). C85 Jacquemier, J., et al., "Prognosis of Breast-Carcinoma Lymphagenesis Evaluated by Immunohistochemical Investigation of Vascular-Endothelial-Growth-Factor Receptor 3," Int. J. Cancer (Pred. Oncol.), 89:69-73 (2000). C86 Jeltsch, "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," Science, 276:1423-1425 (May 30, 1997). C87 Jones, A., et al., "Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis," BJU International, 86:80-86 (2000). C88 Jones, P.T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," Nature, 321:522-525 (May, 1986). C89 Joukov et al., "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," EMBO J., 15(2):290-298 (January 15, 1996).

| | | <u>1</u> | | | |
|----------|------------------|----------|-----------------|------|---|
| EXAMINER | | | DATE CONSIDERED | 63-7 | - |
| | \boldsymbol{N} | | | | _ |

Form PTO-1449 (Modified) APR 2 6 2002 INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C90 Joukov, V. et al., "Proteolytic processing regulates receptor specificity and activity of VEGF-C," EMBO Journal, 16(13):3898-3911 (June, 1997). C91 Joukov, V. et al., "A Recombinant Mutant Vascular Endothelial Growth Factor-c That Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," J Biol Chem., 273(12):6599-602 (1998). C92 Jussila, L. et al., "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," Cancer Res., 58:1599-1604 (April, 1998). C93 Kabashima, A. et al., "Overexpression of Vascular Endothelial Growth Factor C is Related to Lymphogenous Metasasis in Early Gastric Carcinoma," Oncology, 60(2): 146-50 (2001) C94 Kadambi, A. et al., "Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A," Cancer Res. 61(6): 2404-8 (March, 2001). C95 Kaipainen et al., "Expression of the FMS-Like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," Proc. Nat'l Acad. Sci., USA, 92:3566-3570 (April, 1995). C96 Kaipainen et al., "The Related FLT4, FLT1, and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," J. Exp. Med., 178:2077-2088 (December, 1993). C97 Karkkainen, et al., "Missense Mutations Interfere With VEGFR-3 Signalling in Primary Lymphoedema," Nat Genet., 25(2):153-9 (2000). C98 Karkkainen, M.J., et al., "Vascular Endothelial Growth Factor Receptors in the Regulation of Angiogenesis and Lymphangiogenesis," Oncogene, 19(49):5598-605 (November 20, 2000).

| EXAMINER | In | |
|----------|----|--|
| | 77 | |

DATE CONSIDERED

Form PTO-1449 (Modified)

APR 7 6 2002

INFORMATION DISCIPLE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
28967/34891A

Serial No.
09/765,534

Applicant
Alitalo, K. et al.

Filing Date Group
January 19, 2001 1644

| * | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|------|--|
| 1 | C99 | Karpanen, T. et al., "Vascular Endothelial Growth Factor C Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth," Cancer Res. 61(5): 1786-90 (March, 2001). |
| | C100 | Kerstens, H. et al., "A Novel In Situ Hybridization Signal Amplification Method Based on the Deposition of Biotinylated Tyramine," Journal Histochemistry and Cytochemistry, 43(4):347-352 (1995). |
| | C101 | Kettleborough, C.A. et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," Protein Engineering, 4(7):773-783 (1991). |
| | C102 | Kieffer et al., "Uncoupling in the Expression of Platelet GP IIb/IIIa in Human Endothelial Cells and K562 Cells: Absence of Immunologic Crossreactivity Between Platelet GP IIb and the Vitronectin Receptor Alpha Chain," Blood, 72(4):1209-1215 (October, 1988). |
| | C103 | Kim, K.J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature, 362(6423):841-844 (April, 1993). |
| | C104 | Koeffler et al., "Acute Myelogenous Leukemia: A Human Cell Line Responsive to Colony-Stimulating Activity," Science, 200:1153-1154 (1978). |
| | C105 | Köhler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," Nature, 256:495-497 (August 7, 1975). |
| | C106 | Korhonen et al., "Enhanced Expression of the tie Receptor Tyrosine Kinase in Endothelial Cells During Neovascularization," Blood, 80(10):2548-2555 (November 15, 1992). |
| | C107 | Korhonen et al., "The Mouse Tie Receptor Tyrosine Kinase Gene: Expression During Embryonic Angiogenesis," Oncogene (England), 9(2):395-403 (February, 1994). |
| 7 | C108 | Korhonen, J. et al., "Endothelial-Specific Gene Expression Directed by the Tie Gene Promoter in Vivo," Blood (5):1828-35 (1995). |

| | <u> </u> | |
|---------------------------------------|----------|----------------------------|
| EXAMINER | | DATE CONSIDERED (- 3 - 04 |
| , , , , , , , , , , , , , , , , , , , | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Serial No. Atty. Docket No. 09/765,534 28967/34891A

Applicant

Alitalo, K. et al.

Group Filing Date January 19, 2001 1644

INFORMATION DISCLOSURE STATEMENT

| | (U | se several sheets if necessary) | Filing Date January 19, 2001 | 1644 <u>1</u> | 2002 | |
|-----|------|---|-------------------------------|---------------|----------|------------|
| • | | | | П | | |
| | | OTHER DOCUMENTS (Including Au | nthor, Title, Date, Pertinent | Pages, etc.) | AP | ECH CENTER |
| 6 | C109 | Kozbor et al., "The Production of Monoclonal Antibodies From Human Lymphocytes," <i>Immunology Today, 4(3):72-79</i> (1983). | | | | |
| | C110 | Kubo, H., et al., "Involvement of Vascular Endothelial Growth Factor Receptor-3 in Maintenance of Integrity of Endothelial Cell Lining During Tumor Angiogenesis," Blood, 96(2):546-553 (15 July 2000). | | | | |
| | C111 | Kukk et al., "VEGF-C Receptor Binding Suggests A Role in Lymphatic Vascular I 3837 (December, 1996). | | | | |
| · . | C112 | Kurebayashi, J., et al., "Expression of V (VEGF) Family Members in Breast Cancel (September 1999). | | | | |
| | C113 | Laitinen, M. et al., "Adenovirus-mediate Patients With Chronic Critical Leg Ischen (1998). | | | | - |
| | C114 | Lauria, R. et al., "The Prognostic Value of Lymphatic and Blood Vessel Invasion in Operable Breast Cancer," Cancer, 76(10):1772-8 (1995). | | | - | |
| | C115 | Lee et al., "Vascular Endothelial Growth Specific Activator of the Tyrosine Kinase USA, 93:1988-1992 (March, 1996). | | | | |
| | C116 | Leu, A. J. et al., "Absence of Functional Molecular and Functional Evaluation," Co | | | ma: A | _ |
| | C117 | Lhotak et al., "Characterization of Elk, a Mol. Cell. Biol., 11:2496-2502 (May, 199 | | or Tyrosine I | Kinase," | |
| | C118 | Lindberg et al. "cDNA Cloning and Char Receptor Protein-Tyrosine Kinase in the e Cell. Biol., 10:6316-6324 (December, 1996) | ph/elk Family of Prote | | | |
| L | C119 | Lovgren et al., "Time-Resolved Fluorome (Ed.) Alternative Immunoassays, John Wi | | | | |

DATE CONSIDERED

Form PTO-1449 (Modified)

APR 2 6 2002

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A

Applicant

Serial No. 09/765,534

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Alitalo, K. et al.

Filing Date
January 19, 2001

Group 1644

VE 9 2002

| A | - | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|------|--|
| | C120 | Lozzio et al., "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome," Blood, 45(3):321-334 (March, 1975). |
| | C121 | Lyman et al., "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," Cell, 75:1157-1167 (December 17, 1993). |
| | C122 | Lymboussaki, A. et al., "Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors," American Journal of Pathology, 153(2):395-403 (August, 1998). |
| | C123 | Makela et al., "Plasmid pLTRpoly: a Versatile High-Efficiency Mammalian Expression Vector," Gene, 118:293-294 (1992). |
| | C124 | Mandriota, S. J. et al., "Vascular Endothelial Growth Factor-C-Mediated Lymphangiogenesis Promotes Tumour Metastasis," EMBO J., 20(5): 672-82 (February 15, 2001). |
| | C125 | Marchio, S., et al., "Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells," J. Biol. Chem., 274(39):27617-22 (September 24, 1999). |
| | C126 | Marconcini, L., et al., "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro," Proc. Natl. Acad. Sci. USA, 96:9671-76 (August 1999). |
| | C127 | Martin et al., "HEL Cells: A New Human Erythroleukemia Cell Line With Spontaneous Induced Globin Expression," Science, 216:1233-1235 (1982). |
| | C128 | Matthews et al., "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit," Proc. Natl. Acad. Sci. USA, 88(20):9026-9030 (October, 1991). |
| 1 | C129 | Matthews et al., "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," Cell, 65(7):1143-1152 (June 28, 1991). |

| EXAMINER |
|----------|
|----------|

DATE CONSIDERED

2-1-07

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applic

Alitalo, K. et al.

Filing Date

January 19, 2001

Group 1644 IVE 9 2002

(Use several sheets if necessary)

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|-------|---|
| J | C130 | McCutchan et al., "Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylaminoethyl-Dectran," J. Natl. Cancer Inst., 41:351-357 (1968). |
| | C131 | Metzelaar et al., "CD63 Antigen," J. Biol. Chem., 266(5):3239-3245 (February 15, 1991). |
| | C132 | Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis, Cell, 72:835-846 (March 26, 1993). |
| | C133 | Minowada et al., "Brief Communication: Rosette-Forming Human Lymphoid Cell Lines: Establishment and Evidence for Origin of Thymus-Derived Lymphocytes," J. Natl. Cancer Inst., 49:891-895 (1972). |
| | C134 | Mollinedo et al., "Early and Selective Induction of Apoptosis in Human Leukemic Cells By the Alkyl-Lysophospholipid ET-18-OCH ₃ ," Biochem. & Biophys. Res. Comm., 192(2):603-609 (April 30, 1993). |
| | C135 | Moriyama, M., et al., "Immunohistochemical Study of Tumour Angiogenesis in Oral Squamous Cell Carcinoma," Oral Oncol., 33(5):369-74 (September 1997). |
| | C136 | Moroni et al., "EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line," J. Biol. Chem., 267(5):2714-2722 (February 5, 1992). |
| | ·C137 | Morrison, S.L. et al., "Genetically Engineered Antibody Molecules," Advances in Immunology, 44:65-92 (1989). |
| | C138 | Mortimer, P. S., "The Pathophysiology of Lymphedema," Cancer, 83 (12 Suppl American):2798-802 (1998). |
| | C139 | Moshakis, V. et al., "Localization of human breast-carcinoma xenografts using antibodies to carcinoembryonic antigen," Br. J. Cancer, 43:575-581 (1981). |
| K | C140 | Mukkala et al., "The Synthesis and Use of Activated N-Benzyl Derivatives of Diethylenetriaminetetraacetic Acids: Alternative Reagents for Labeling of Antibodies with Metal Ions," Annal. Biochem, 176:319-325 (1989). |

| EXAMINER | m |
|----------|---|
| | |

DATE CONSIDERED

6707

| Form PTO-1449 (I | Modified) | S. Department of Commerce | Docket No. 28967/34891A | Serial No. 09/765,534 |
|---------------------------------|-----------|---|--|--------------------------|
| INFORMATION DISCLOSURE TATEMENT | | | Applicant Alitalo, K. et al. | Q |
| , III 014 | | OIPE PADEMARKS | Filing Date | Group S |
| | <u> </u> | se several stores if necessary) | January 19, 2001 | 1644 5 5 |
| | AP | R Z 2002) | | O g |
| A | (St. | PADEMAN THER DOCUMENTS (Including A | uthor, Title, Date, Pertinent | Pages, etc.) |
| | C141 | Mustonen et al., "Endothelial Receptor T Angiogenesis," J. Cell Biology, 129(4):8 | | ved in |
| . / | C142 | Nathanson, S.D., et al., "Microvessels Metastases in Patients With Breast Cance | - | · - |
| | C143 | Nicosia, R.F., "What Is the Role of Vasc Molecules in Tumor Angiogenesis?" Am. | and the second s | · |
| | C144 | Niki, T., et al., "Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma," Clin. Cancer Res., 6(6):2431-9 (June 2000). | | |
| | C145 | Niki, T. et al., "Expression of Vascular I Blood and Lymphatic Vessels of Lung Ac (April, 2001). | | |
| | C146 | Nowell et al., "Chromosome Studies in P versus Cytopenic Disorders," Cancer, 42 | _ | eloproliferative |
| | C147 | Oelrichs et al., "NYK/FLK-1: A Putative From E10 Embryonic Neuroepithelium is Developing Embryo," Oncogene, 8(1):11 | Expressed in Endothe | |
| | C148 | Oh et al., "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," Developmental Biology, 188:96-109 (1997). | | |
| | C149 | Ohta, Y., et al., "Increased Vascular En Endothelial Growth Factor-C and Decrea Microdissemination in the Lymph Nodes J. Thorac Cardiovasc Surg, 119(4 Pt 1):8 | sed NM23 Expression in Stage 1 Non-Small | Associated with |
| | €150 | Ohta, Y., et al., "VEGF and VEGF type and lymphangiogenesis in human maligna 81(1):54-61 (September 1999). | | |

| EXAMINER | | DATE CONSIDERED | 6-7-04 |
|----------|---|-----------------|--------|
| | erence considered, whether or not cital | | |

| alpe . | | SHEET 18 01 27 |
|--|----------------------------------|---|
| Form PTO-1449 (Modified) JU.S. Department of Commerce Patent and Trademark Office | Ally. Docket No. 28967/34891A | Serial No. 09/765,534 |
| INFORMATION DISCLOSURE STATEMENT | Applicant Alitalo, K. et al. | ED 02 |
| (Use several sheets if necessary) | Filing Date January 19, 2001 | Group > 07 6 6 1644 11 2 |
| | €* | S B B B B B B B B B B B B B B B B B B B |

| | | III A C |
|---|------|--|
| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
| | C151 | O'Reilly, M.S. et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 79(2):315-328 (October, 1994). |
| | C152 | O'Reilly, M.S. et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, 88(2):277-285 (January, 1997). |
| | C153 | Padlan, E.A., "A Possible Procedure For Reducing The Immunogenicity Of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," <i>Molecular Immunology</i> , 28(4/5):489-498 (1991). |
| | C154 | Pajusola et al., "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin- Like Loops and is Expressed in Multiple Human Tissues and Cell Lines," Cancer Research, 52(20):5738-5743 (October 15, 1992). |
| | C155 | Pajusola et al., "Two Human FLT4 Receptor Tyrosine Kinase Isoforms With Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," Oncogene, 8:2931-2937 (1993). |
| | C156 | Pajusola, "Cloning and Characterization of a New Endothelial Receptor Tyrosine Kinase FLT4 and Two Novel VEGF-Like Growth Factors VEGF-B and VEGF-C," Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Department of Biosciences, Division of Genetics, University of Helsinki, Academic Dissertation, Helsinki 1996. |
| | C157 | Pajusola et al., "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related To Two VEGF Receptors," Oncogene, 9:3545-3555 (1994). |
| | C158 | Parker, S. H., et al., "Identification of the Sentinel Node in Patients With Breast Cancer," Radiol Clin North Am," 38(4):809-23 (2000). |
| | C159 | Partanen et al., "Putative Tyrosine Kinases Expressed in K-562 Human Leukemia Cells," Proc. Nat'l Acad. Sci., USA, 87(22):8913-8917 (November, 1990). |
| 4 | £160 | Partanen et al., "A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains," Mol. Cell. Biol., 12(4):1698-1707 (April, 1992). |

| EXAMINER | DATE CONSIDERED 6 3 27 |
|----------|---|
| | r or not citation is in conformance with MPEP 609; Draw line through clude copy of this form with next communication to applicant |

(Use several sheets if necessary)

January 19, 2001

1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C161 Partanen, T.A., et al., "Lack of Lymphatic Vascular Specificity of Vascular Endothelial Growth Factor Receptor 3 in 185 Vascular Tumors," Cancer, 86(11): 2406-12 (December 1, 1999). Patent Cooperation Treaty Search Report for PCT/US 99/23525 C162 C163 Paulsson, G. et al., "The Balbiani Ring 3 Gene in Chironomus Tentans Has a Diverged Repetitive Structure Split by Many Introns," J. Mol. Biol., 211:331-49 (1990) C164 Pepper, M. S., "Lymphangiogenesis and Tumor Metastasis: Myth or Reality?," Clinical Cancer Res., 7: 462-68 (March, 2001). C165 Perumov et al., "Influence of Antisense RNA's of Interleukin-1β and Interleukin-1 Receptor Antagonist on Interleukin-1\beta Production," J. Cell. Biochem., Supplement. 16 pt B:285 (ABSTRACT J216) (1992). Peters et al., "Vascular Endothelial Growth Factor Receptor Expression During C166 Embryogenesis and Tissue Repair Suggests a Role in Endothelial Differentiation and Blood Vessel Growth," Proc. Nat'l Acad. Sci., USA, 90:8915-8919 (October, 1993). C167 Peterson, C. and Legerski, R., "High-frequency Transformation of Human Repairdeficient Cell Lines by an Epstein-Barr Virus-based cDNA Expression Vector." Gene, 107: 279-84, (1991). C168 Pietersz et al., "Antibody Conjugates for the Treatment of Cancer," Immunological Reviews, 129:57-80 (1992). C169 Plückthun, A. et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," Immunotechnology, 3:83-105 (1997). C170 Poncz et al., "Cloning and Characterization of Platelet Factor 4 cDNA Derived From a Human Erythroleukemic Cell Line," Blood, 69(1):219-223 (January, 1987). C171 Rader, C. et al., "Phage Display of Combinatorial Antibody Libraries." Curr. Opin. Biotech., 8:503-508 (1997).

| EXAMINER | | DATE CONSIDERED (-) ~ 7 | | |
|---|--|-------------------------|--|--|
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

Atty. Docket No.
28967/34891A

Applicant
Alitalo, K. et al.

Filing Date
January 19, 2001

Serial No.
09/765,534

| | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | |
|----|--|--|--|--|
| J. | C172 | Reedijk et al., "Tyr721 Regulates Specific Binding of the CSF-1 Receptor Kinase Insert to P1 3'-Kinase SH2 Domains: a Model for SH2-Mediated Receptor-Target Interactions," EMBO J., 11(4):1365-1372 (1992). | | |
| | C173 | Relf, M. et al., "Expression of the Angiogenic Factors Vascular Endothelial Cell Growth Factor, Acidic and Basic Fibroblast Growth Factor, Tumor Growth Factor β-1, Platelet-derived Endothelial Cell Growth Factor, Placenta Growth Factor, and Pleiotrophin in Human Primary Breast Cancer and Its Relation to Angiogenesis," Cancer Research, 57:963-969 (March, 1997). | | |
| | C174 | Renner, C. et al., "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," <i>Immunological Reviews, No.145</i> , pp. 179-209 (1995). | | |
| | C175 | Riechmann, L. et al., "Reshaping human antibodies for therapy," Nature, 332(6162):323-327 (March, 1988). | | |
| | C176 | Roitt, M., "Essential Immunology," Blackwell Scientific Pub., Oxford, pp.65-68 & 74 (1991). | | |
| | C177 | Rosnet et al., "Isolation and Chromosomal Localization of a Novel FMS-Like Tyrosine Kinase Gene," Oncogene, 6(9):1641-1650 (1991). | | |
| | C178 | Rosnet et al., "Murine Flt3, a Gene Encoding a Novel Tyrosine Kinase Receptor of the PDFR/CSF1R Family," Genomics, 9:380-385 (1991). | | |
| | C179 | Saaristo, A., et al., "Vascular Endothelial Growth Factor-C and its Receptor VEGFR-3 in the Nasal Mucosa and in Nasopharyngeal Tumors," Am. J. Pathology, 157(1):7-14 (July 2000). | | |
| | C180 | Sabin, F.R., "The Lymphatic System in Human Embryos, with Consideration of the Morphology of the System as a Whole," <i>Am. J. Anat.</i> , 9(1):43-91 (1909). | | |
| | C181 | Salven, P. et al., "Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors," <i>American J. Pathology</i> , 153(1):103-108 (July, 1998). | | |
| | C182 | Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, pp. 2.60-2.70, 4.21-4.32, 7.3-7.36 (1989). | | |

| EXAMINER | h | DATE CONSIDERED | 67-07 |
|---|--|-----------------------------|--|
| *EXAMINER: Initial if r citation if not in conform | reference considered, whether or not cital nance and not considered. Include copy | tion is in conformance with | n MPEP 609; Draw line through munication to applicant. |

SHEET 21 of 27

| | | SHEET 21 01 27 |
|--|----------------------------------|--------------------------|
| Form PTO-1449 (Modified) S. Department of Commerce of Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 |
| INFORMATION DISCLOSURE STATEMENT | Applicant Alitalo, K. et al. | Ω |
| (Use several sheets if necessary) | Filing Date January 19, 2001 | Group Д 2007 6 |
| | | Ш 2 |

| <u> </u> | | <u> </u> |
|----------|------|--|
| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
| | C183 | Sato and Seiki, "Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells," <i>Oncogene</i> , 8:395-405 (1993). |
| | C184 | Satoh et al., "Regional Localization of the Human c-ros-1 on 6q22 and flt on 13q12," Jpn. J. Cancer Res., 78:772-775 (1987). |
| | C185 | Schlessinger, J., "Cell Signaling by Receptor Tyrosine Kinases," <i>Cell</i> , 103(2): 211-25 (October 13, 2000). |
| | C186 | Schneider et al., "A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix," J. Biol. Chem., 257(18):10766-10769 (September 25, 1982). |
| - | C187 | Schreiber et al., "Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition," Proc. Nat'l Acad. Sci., 82:6138-6142 (September, 1985). |
| | C188 | Schwenk et al., "Cell Cycle Dependency of a T-Cell Marker on Lymphoblasts," Blut, 31:299-306 (1975). |
| | C189 | Scott, P.A.E. et al., "Laboratory-Clinic Interface: Current approaches to targeting cancer using antiangiogenesis therapies," Cancer Treatment Reviews, 20:393-412 (1994). |
| | C190 | Segal, D.M. et al., "Alternative Triggering Molecules and Single Chain Bispecific Antibodies," Journal of Hematotherapy, 4:377-382 (1995). |
| | C191 | Segal, D.M. et al., "Targetting of Anti-Tumor Responses with Bispecific Antibodies," <i>Immunobiology</i> , 185(2-4):390-402 (August, 1992). |
| | C192 | Sherr et al., "The c-fms Proto-Oncogene Product is Related to the Receptor for the Mononuclear Phagocyte Growth Factor, CSF-1," Cell, 41:665-676 (July, 1985). |
| + | C193 | Shi et al., "16-Kilodalton Heparin Binding (Fibroblast) Growth Factor Type One Appears in a Stable 40-Kilodalton Complex After Receptor-Dependent Internalization," J. Biol. Chem., 266(9):5774-5779 (March 25, 1991). |

| | A | | |
|--------------------|---|-----------------------------|--------------------------------|
| EXAMINER | M | DATE CONSIDERED | 6.3-07 |
| *EXAMINER: Initial | f reference considered, whether or not cita | tion is in conformance with | MPED 600. Described the street |

SHEET 22 of 27

| | | SHEET 2 | .Z OI Z/ |
|---|----------------------------------|--------------------------|----------|
| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 | |
| INFORMATION DECLOSISE STATEMENT | Applicant Alitalo, K. et al. | <u> </u> | 20 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Filing Date January 19, 2001 | Group | 9 20 |
| | | $\overline{\mathbf{O}}$ | ά |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|-----|----|---|
| | Cı | Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor- Type Tyrosine Kinase Gene (flt) Closely Related to the fms Family," Oncogene, 5:519-524 (1990). |
| | C1 | Shibuya, M., "Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis," Advances in Cancer Research, 67:281-316 (1995). |
| | C1 | Shushanov, S., et al., "VEGFc and VEGFR3 Expression in Human Thyroid Pathologies," Int. J. Cancer, 86:47-52 (2000). |
| | Cı | Skobe, M., et al., "Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi's Sarcoma," J. Invest. Dermatology, 113:1047-1053 (1999). |
| · | C1 | Skobe, M. et al., "Induction of Tumor Lymphangiogenesis by VEGF-C Promotes Breast Cancer Metastasis," Nat. Med., 7(2): 192-8 (February, 2001). |
| | C1 | Sowter, H.M., et al., "Expression and Localization of the Vascular Endothelial Growth Factor Family in Ovarian Epithelial Tumors," Lab. Invest., 77(6):607-14 (December 1997). |
| | C2 | Stacey et al., "SVpoly: A Versatile Mammalian Expression Vector," Nucl. Acids Res., 18(9):2829 (1990). |
| | C2 | Stacker, S. A., "VEGF-D Promotes the Metastatic Spread of Tumor Cells Via the Lymphatics," <i>Nat. Med., 7(2)</i> : 186-91 (February, 2001). |
| · , | C2 | Staunton et al., "The Arrangement of the Immunoglobulin-Like Domains of ICAM-1 and the Binding Sites for LFA-1 and Rhinovirus," Cell, 61:243-254 (April 20, 1990). |
| | C2 | Stenman et al., "Human PDGFA Receptor Gene Maps to the Same Region on Chromosome 4 as the KIT Oncogene," Genes, Chromosomes, Cancer, 1:155-158 (1989). |
| Ą | C2 | Stohrer <i>et al.</i> , "Oncotic Pressure in Solid Tumors is Elevated," Cancer Res, 60: 4251-5, (2000). |

| | <u> </u> | |
|-----------------------|---|--|
| EXAMINER | | DATE CONSIDERED (2)-07 |
| *EXAMINER: Initial if | reference considered, whether or not citanance and not considered. Include copy | tion is in conformance with MPEP 609; Draw line through of this form with next communication to applicant. |

| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 28967/34891A | Serial No. 09/765,534 | |
|---|----------------------------------|-----------------------|------|
| INFORMATION DISE OSUBESTATEMENT. | Applicant Alitalo, K. et al. | | - |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Filing Date January 19, 2001 | Group | 2002 |
| | | | |

| | | |
|----------|------|--|
| <i>A</i> | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
| | C205 | Sundström <i>et al.</i> , "Establishment and Characterization of a Human Histiocytic Lymphoma Cell Line (U-937)," <i>Int. J. Cancer</i> , 17:565-577 (1976). |
| | C206 | Swolin et al., "On the 5q-Deletion: Clinical and Cytogenetic Observations in Ten Patients and Review of the Literature," Blood, 58:986-993 (1981). |
| | C207 | Taipale, J. et al., "Vascular Endothelial Growth Factor Receptor-3," Curr Top Microbiol Immunol., 237:85-96 (1999). |
| | C208 | Tang, R. F. et al., "Overexpression of Lymphangiogenesis Growth Factor VEGF-C in Human Pancreatic Cancer," Pancreas, 22(3): 285-92 (April, 2001). |
| | C209 | Tekmal, R.R. et al., "A Novel in Vitro and in Vivo Breast Cancer Model for Testing Inhibitors of Estrogen Biosynthesis and Its Action Using Mammary Tumor Cells With an Activated int-5/aromatase Gene," Cancer Letters, 118(1):21-28 (September, 1997). |
| | C210 | Tempest, P.R. et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo," BioTechnology, 9(3):266-271 (March, 1991). |
| | C211 | Terman et al., "Identification of a New Endothelial Cell growth Factor Receptor Tyrosine Kinase," Oncogene, 6(9):1677-1683 (1991). |
| | C212 | Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," Biochem & Biophys. Res. Comm., 187(3):1579-1586 (September 30, 1992). |
| | C213 | Thompson et al., "Cloned Human Teratoma Cells Differentiate into Neuron-Like Cells and Other Cell Types in Retinoic Acid," J. Cell Sci., 72:37-64 (1984). |
| | C214 | Thurston, G. et al., "Leakage-resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1," Science, 286(5449):2511-4 (1999). |
| + | C215 | Tomiyasu et al., "Long Arm Deletion of Chromosome No. 5 in a Case of Philadelphia Chromosome-Positive Chronic Myelocytic Leukemia," Cancer Genet. Cytogenet., 2:309-315 (1980). |

| EXAMINER | DATE CONSIDERED 6-3-07 |
|---------------------------------|--|
| *FXAMINER: Initial if reference | considered, whether or not citation is in conformance with MPEP 600. Draw line through |

Form PTO-1449 (Modified) APR 2 5 2002 INFORMATION DISCLOSIFIE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|----------|------|---|
| f | C216 | Tortora et al., "Differentiation of HL-60 Leukemia By Type I Regulatory Subunit Antisense Oligodeoxynucleotide of a cAMP-Dependent Protein Kinase," Proc. Nat'l Acad. Sci., USA, 88(5):2011-2015 (March, 1991). |
| | C217 | Traunecker, A. et al., "Myeloma based expression system for production of large mammalian proteins," <i>Trends in BioTechnology</i> , 9(4):109-113 (April, 1991). |
| | C218 | Tsurusaki, T., et al., "Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis," Br. J. Cancer, 801(2):309-313 (1999). |
| | C219 | Ullrich et al., "Signal Transduction By Receptors with Tyrosine Kinase Activity," Cell, 61:203-212 (April 20, 1990). |
| | C220 | Valtola, R., et al., "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," Am. J. Pathol., 154(5):1381-90 (May 1999). |
| | C221 | van der Putte, S.C.J., "The Development of the Lymphatic System in Man," Adv. Anat. Embryol. Cell Biol., 51:3 (1975). |
| | C222 | Van Den Berghe et al., "Distinct Haematological Disorder with Deletion of Long Arm of No. 5 Chromosome." Nature, 251:437-439 (1974). |
| | C223 | Van Den Berghe et al., "Transformation of Polycythemia Vera to Myelofibrosis and Late Appearance of a 5q-Chromosome Anomaly," Cancer Genet. Cytogenet., 1:157-162 (1979). |
| | C224 | Van Hinsberg et al., "Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells," <i>Thromb. Haemostas.</i> , 57(2):148-153 (1987). |
| | C225 | Van Hinsberg et al., "Production of Plasminogen Activators and Inhibitors by Serially Propagated Endothelial Cells From Adult Human Blood Vessels," Arteriosclerosis, 7:389-400 (July/August, 1987). |
|) | C226 | Veikkola, T., et al., "Regulation of Angiogenesis Via Vascular Endothelial Growth Factor Receptors," Cancer Res., 60(2):203-12 (2000). |

| EXAMINER | DATE CONSIDERED (-)-07 |
|---|------------------------|
| *EXAMINER: Initial if reference considered, whether or not cital citation if not in conformance and not considered. Include copy of | |

| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Ally. Docket No. 28967/34891A | Serial No. 09/765,534 |
|---|----------------------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | Applicant Alitalo, K. et al. | Ω |
| (Use several sheets if necessary) | Filing Date January 19, 2001 | Group 2007 6 |
| | | Ш ~ |

| | | O & |
|---|-------------|--|
| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
| | C227 | Verhoeyen, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536 (March, 1988). |
| | C228 | Wang, "Signal Transduction in Human Hematopoietic Cells by Vascular Endothelial Growth Factor Related Protein, a Novel Ligand for the FLT4 Receptor," Blood, 90(9):3507-3515 (November, 1997). |
| | C229 | Warrington et al., "Radiation of Hybrid Map of 13 Loci on the Long Arm of Chromosome 5," Genomics, 11:701-708 (1991). |
| | C230 | Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma," J. Natl. Cancer Inst., 84(24):1875-1887 (December, 1992). |
| | C231 | Wen, D. et al., "New Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," Cell, 69:559-572 (May 1, 1992). |
| | C232 | Weninger, W., et al., "Expression of Vascular Endothelial Growth Factor Receptor-3 and Podoplanin Suggests a Lymphatic Endothelial Cell Origin of Kaposi's Sarcoma Tumor Cells," Lab. Invest., 79(2):243-51 (February 1999). |
| | C233 | Whang-Peng et al., "Cytogenic Studies in Patients With Myelofibrosis and Myeloid Metaplasia," Leuk. Res., 2:41-48 (1978). |
| | C234 | Wilkinson et al., "Expression of the Proto-Oncogene int-1 is Restricted to Specific Neural Cells in the Developing Mouse Embryo," Cell, 50:79-88 (1987). |
| | C235 | Williams, A.F. and Barclay, A.N., "The Immunoglobin Superfamily-Domains for Cell Surface Recognition," Ann. Rev. Immunol., 6:381-405 (1988). |
| | C236 | Williams, J.C. et al., "N-methyl-N-nitrosourea-Induced Rat Mammary Tumors. Hormonal Responsiveness but Lack of Spontaneous Metastasis," J. Nat. Cancer Inst., 66(1):147-155 (January, 1981). |
| 1 | C237 | Witte et al., "Lymphangiogenesis: Mechanisms, Significance and Clinical Implications," in Regulation of Angiogenesis (eds. Goldberg, I.D. & Rosen, E. M.) 65-112 (birkhauser Verlag, Basel, Switzerland) 1997. |

| EXAMINER | DATE CONSIDERED (2) -4 7 |
|---|---|
| *EXAMINER: Initial if reference considered, whether or not cita | tion is in conformance with MPFP 609. Draw line through |

Form PTO-1449 (Modified)

APR 2 6 2002

INFORMATION DISCESSIFE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. Serial No. 28967/34891A 09/765,534

Applicant

Alitalo, K. et al.

Filing Date
January 19, 2001

Group 1644 **200**%


| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|
| Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," American Journal of Pathology, Vol. 153, No.2:381-394 (August 1998). |
| Yamaguchi et al., "Flk-1, an Flt-Related Tyrosine Kinase is an Early Marker for Endothelial Cell Precursors," Development., 118:489-498 (1993). |
| Yarden et al., "Human Proto-Oncogene c-kit: A New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand," EMBO J., 6(11):3341-3351 (1987). |
| Ylänne et al., "Platelet Glycoprotein IIb/IIIa Complex in Cultured Cells: Localization in Focal Adhesion Sites in Spreading HEL Cells," Blood, 72: 1478-1486 (1988). |
| Yokoyama, Y., et al., "Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial Carcinoma," Gyn. Oncology 77:413-418 (2000). |
| Yonemura, Y., et al., "Role of Vascular Endothelial Growth Factor C Expression in the Development of Lymph Node Metastasis in Gastric Cancer," Clin. Cancer Res., 5:1823-1829 (July 1999). |
| Yonemura, Y. et al., "Lymphangiogenesis and the Vascular Endothelial Growth Factor Receptor (VEGFR)-3 in Gastric Cancer," Eur. J. Cancer, 37(7): 918-23 (May, 2001). |
| Dias, et al., "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," Blood, 99:2179-2184 (2002) |
| Karkkainen, et al., "Lymphatic endothelium: a new frontier of metastasis research," Nat. Cell. Biol. 4:E2-E5 (2002) |
| Makinen, et al., "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," Nat. Med. 7:199-205 (2001) |
| Mattila, et al., "VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors," Int. J. Cancer 98:946-951 (2002) |
| |

EXAMINER

DATE CONSIDERED /

7.77

SHEET 27 of 27



| - <u>-</u> | . , | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|------------|------|--|
| K | C249 | Siemeister, et al., "Two Independent Mechanicsms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering With Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," Cancer Res. 59:3185-91 (1999) |
| 1/ | C250 | Witmer, et al., "VEGFR-3 in adult angiogenesis," J. Path. 195:490-497 (2001) |

TECHNING STATES OF STATES

EXAMINER

DATE CONSIDERED